Researchers evidence suggests it’s the lessening of amyloid-beta in the brain that is behind cognitive decline.

A study shows that rising levels of brain protein Aβ42, not the reduction of amyloid plaques, better explains the cognitive ...

Boosting a certain brain protein could help slow the progression of Alzheimer’s disease, a new study has found. The ...

In the past two years, the U.S. Food and Drug Administration has approved two monoclonal antibody treatments to slow ...

A study published Wednesday in Nature Neuroscience sheds light into how amyloid-beta and tau proteins impact brain activity ...

This year's World Alzheimer's Day campaign aims to address the stigma and discrimination while highlighting global efforts to ...

Leqembi and Kisunla don’t just reduce amyloid plaques that are implicated in Alzheimer’s disease. According to new research, ...

Despite enormous effort, disease-modifying therapies for Alzheimer's disease, the most common cause of dementia, have proven ...

Researchers discover how amyloid-β and tau pathologies interact to drive early neurophysiological changes and cognitive ...

GE HealthCare’s recently acquired MIM Software division has secured an FDA clearance for a tool to help quantify the density ...

The next generation of Alzheimer’s therapeutics is moving away from amyloid plaques and tau tangles, offering multiple ...